MiMedx Group, Inc
MDXGBiotechnology
$3.97+0.51%As of Oct 29vs prior close
- Market cap
- $579.4M
- P/E (TTM)
- –
- From 52W high
- −50.13%
- EPS (LTM)
- -$0.13
- Revenue (LTM)
- $303.7M
- Net margin
- -6.32%
- Dividend yield
- 0.00%
Nomior Score
41
Steady ProfileSpeculativeBottom 31% of the scored universe
Growth42
Quality65
Value58
Momentum9
Resilience54
Growth
+7.32%revenue a year over 9 fiscal years
YE16 $221.7MLTM $303.7M
Connections
Revenue to profitQ3 YE26
The operating loss was 19% of revenue, wider by 38 pts on a year.
Latest resultsthird quarter 2026
- Revenue
- $62 million
- Net loss
- $9 million
- Revenue outlook
- $250 to $260 million
Net sales fell sharply from the prior year period, driven by a steep decline in Wound sales after Medicare reimbursement changes, while Surgical sales grew on strong volume. Gross margin and operating costs improved sequentially after cost reductions, and the company returned to positive Adjusted EBITDA. The company narrowed its full-year net sales outlook and expects fourth quarter Adjusted EBITDA to be sequentially higher than the third quarter.
Who owns it
2funds